| # | Country | Total Patents | |
|---|---|---|---|
| #1 | WIPO (World Intellectual Property Organization) | 6 | |
| #2 | Australia | 5 | |
| #3 | Canada | 2 | |
| #4 | EPO (European Patent Office) | 1 | |
| #5 | Finland | 1 | |
| #6 | Israel | 1 | |
| #7 | Japan | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Heterocyclic compounds | |
| #2 | Medical preparations | |
| #3 | Therapeutic chemical compounds | |
| #4 | Acyclic or carbocyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Cai Sui Xiong | 16 |
| #2 | Keana John F W | 14 |
| #3 | Weber Eckard | 11 |
| #4 | Kher Sunil | 4 |
| #5 | Martin Vladimir V | 3 |
| #6 | Lan Nancy C | 3 |
| #7 | Woodward Richard M | 3 |
| #8 | Nogales Daniel F | 2 |
| #9 | Guzikowski Anthony P | 2 |
| #10 | Zhou Zhang-Lin | 2 |
| Publication | Filing date | Title |
|---|---|---|
| AU1463997A | Subtype-selective nmda receptor ligands and the use thereof | |
| AU6172696A | 4,5-bridged quinoxalinediones and quinolones and the use thereof as excitatory amino acid receptor antagonists | |
| WO9602250A1 | Haloperidol analogs and the use thereof | |
| CA2180122A1 | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the usethereof as antagonists for the glycine/nmda receptor |